Effect of Polymer Type and Preparation of Cilnidipine Preformulation Study)
Keywords:
Cilnidipine, Poloxamers 188, PVA cold, PVP K30, Soloplus®Abstract
Cilnidipine is a dihydropyridine calcium channel blocker used to improve the neurological outcome following subarachnoid hemorrhage. It belongs to BCS class II drugs that have a low oral bioavailability of 13%.This study aimed to prepare Cilnidipine as nanoparticles using different polymers which would be expected to improve bioavailability. Cilnidipine nanoparticles were prepared by solvent anti-solvent method by using different types of polymers (PVP K30, HPMC E5, Soloplus®, Poloxamers 188, PVA cold) in different ratios. Different formulation variables were changed. Based on the obtained results, formula P1, which included Soloplus in a 1:1 weight ratio of drug to polymer, exhibited a particle size of 140.4 nm when stirred at 1000 rpm with an injection speed of 1 ml/min. The polydispersity index (PDI) for this formula was measured at 0.264. Furthermore, formula P1 demonstrated an impressive 90.12% drug content and an entrapment efficiency (EE) of 92.7%.
Downloads
References
Kanikkannan N. Technologies to Improve the Solubility,
Dissolution and Bioavailability of Poorly Soluble Drugs. J
Anal Pharm Res. 2018;7(1):1-6.
Jagtap S, Magdum C, Jadge D, Jagtap R. Solubility
enhancement technique: A review. J Pharm Sci Res.
O18;1O(9):22O5-11.
Kokilambigai Ks, Lakshmi Ks. Innovare Academic Sciences
Review Article Analytical Methodologies For
Determination Of Cilnidipine: An Overview. 2014;6(6).
Upadhay M. Preparation and evaluation of Cilnidipine
microemulsion. In: Journal of Pharmacy and Bioallied
Sciences. 2012. p. 114-5.
Ministerial W, No N, Paragraph P, Law A, No L. The Ministry
of Health , Labour and. Powder Diffr. 2OO7;2OO7(285):1-
Hoshide S, Kario K, Ishikawa J, Eguchi K, Shimada K.
Comparison of the Effects of Cilnidipine and Amlodipine
on Ambulatory Blood Pressure. 2OO5;28(12):1OO3-8.
Aundhia C, Shah N, Patel S, Sen AK, Patel P. Formulation
and evaluation of floating tablet of norfloxacin. Int J
Pharm Res. 2O2O;12(1):622-7.
Nagar SK, Soniwala MM. Optimization of Cilnidipine
Nanosuspension Using a Center Composite Design. Int J
Pharm Sci Drug Res. 2017;9(04):149-59.
Remya PN, Damodharan N. Formulation, development, and
characterisation of Cilnidipine loaded solid lipid
nanoparticles. Asian J Pharm Clin Res. 2018;11(9):120-5.
Srinivas NSK, Verma R, Kulyadi GP, Kumar L. A quality by
design approach on polymeric nanocarrier delivery of
gefitinib: Formulation, in vitro, and in vivo
characterization. Int J Nanomedicine. 2017;12:15-28.
Mastiholimath VS, Bhagat Ankita R, Mannur VS, Dandagi
PM, Gadad AP, Khanal P. Formulation and evaluation of
cefixime nanosuspension for the enhancement of oral
bioavailability by solvent-antisolvent method and its
suitable method development. Indian J Pharm Educ Res.
;54(1):55-67.
Hemke AT, Bhure M V., Chouhan KS, Gupta KR, Wadodkar
SG. UV spectrophotometric determination of
hydrochlorothiazide and olmesartan medoxomil in
pharmaceutical formulation. E-Journal Chern.
;7(4):1156-61.
Patel A, Panchai A, Patel V, Nagar A. FTIR spectroscopic
method for quantitative analysis of Cilnidipine in tablet
dosage form. Int J Pharma Sci Res. 2O15;6(7):1O33.
Yang H, Teng F, Wang P, Tian B, Lin X, Hu X, et al.
Investigation of a nanosuspension stabilized by Soluplus®
to improve bioavailability. Int J Pharm. 2014;477(1-
:88-95.
Alhagiesa AW, Ghareeb MM. Formulation and
Characterization of Nimodipine Nanoparticles for the
Enhancement of solubility and dissolution rate. Iraqi J
Pharm Sci. 2021;30(2):143-52.
Kim, M. S., Song, H. S., Park, H. J. and Hwang, S. J. Effect of
solvent type on the nanoparticle formation of
atorvastatin calcium by the supercritical antisolvent
process. Chemical and Pharmaceutical Bulletin,2012;
(4).
Rashid, A. M. and Abd-Alhammid, S. N. Formulation and
characterization of itraconazole as nanosuspension
dosage form for enhancement of solubility. Iraqi Journal
of Pharmaceutical Sciences,2019; 28(2).
Alwan, R. M. and Rajab, N. A. Nanosuspensions of
Selexipag: Formulation, Characterization, and in vitro
Evaluation. Iraqi Journal of Pharmaceutical
Sciences,2021; 30(1).
Dora CP, Singh SK, Datusalia AK, Deep A. Development and
characterization of nanoparticles of glibenclamide by
solvent displacement method. 2010; Acta Poloniae
Pharmaceutica -Drug Research.2010; 67(3 ): 283-290.
Al-Obaidy RAR, Rajab NA. Preparation and In-vitro
Evaluation of Darifenacin HBr as Nanoparticles
Prepared as Nanosuspension. Int J Drug Deliv Technol.
O22;12(2):775-81.
Sundar VD, Divya P, Sridevi P, Akhila K, Dhanaraju MD.
Design, formulation and evaluation of nanosuspension
for drug delivery of celecoxib. Int J Pharm Res.
;11(1):139-46.
Rashid AM, Abd-Alhammid SN. Formulation and
characterization of itraconazole as nanosuspension
dosage form for enhancement of solubility. Iraqi J Pharm
Sci. 2019;28(2):124-33.
Shaikh F, Patel M, Patel V, Patel A, Shinde G, Shelke S,
Pathan I. Formulation and optimization of Cilnidipine
loaded nanosuspension for the enhancement of
solubility, dissolution and bioavailability. Journal of Drug
Delivery
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
